Drug Approval | March 02, 2024
Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg
The product will be launched in March 2024
The product will be launched in March 2024
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
BHL will undertake the development and supply of these molecules
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine
The facility will accommodate over 1,500 employees
Subscribe To Our Newsletter & Stay Updated
